Michael Schmidt
Stock Analyst at Guggenheim
(4.97)
# 19
Out of 5,090 analysts
119
Total ratings
75.27%
Success rate
55.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $4.36 | +175.23% | 1 | Nov 7, 2025 | |
| INCY Incyte | Upgrades: Buy | $125 | $102.52 | +21.93% | 7 | Nov 3, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $31.74 | +35.48% | 3 | Sep 23, 2025 | |
| IMNM Immunome | Reiterates: Buy | $25 | $19.76 | +26.52% | 3 | Aug 25, 2025 | |
| MRSN Mersana Therapeutics | Maintains: Buy | $125 → $30 | $27.78 | +8.01% | 4 | Aug 14, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $3.29 | +203.95% | 6 | Aug 13, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Buy | $18 | $11.00 | +63.64% | 6 | Aug 13, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $10 → $12 | $5.53 | +117.00% | 5 | Aug 12, 2025 | |
| ONC BeOne Medicines AG | Maintains: Buy | $350 → $365 | $322.90 | +13.04% | 4 | Aug 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $16 → $15 | $12.79 | +17.28% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $10 | $9.63 | +3.84% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $38.77 | -56.15% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $79.64 | +0.45% | 4 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $24.69 | +82.26% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $22.98 | -34.73% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $66.62 | -21.95% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $7.68 | +30.21% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $20.32 | +57.48% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $21.15 | -62.17% | 2 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 | $96.14 | +13.38% | 5 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $10.36 | +35.14% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $28.13 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $44.36 | -5.32% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.53 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.58 | +258.42% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.39 | +475.54% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $38.78 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.53 | +1,210.37% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.42 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.40 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $17.30 | +96.53% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.27 | +664.53% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $17.41 | +72.31% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $5.46 | +376.19% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.74 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $27.73 | +188.50% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.92 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.42 | +24.43% | 2 | Nov 7, 2017 |
Foghorn Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $4.36
Upside: +175.23%
Incyte
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $102.52
Upside: +21.93%
Genmab
Sep 23, 2025
Upgrades: Buy
Price Target: $43
Current: $31.74
Upside: +35.48%
Immunome
Aug 25, 2025
Reiterates: Buy
Price Target: $25
Current: $19.76
Upside: +26.52%
Mersana Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $125 → $30
Current: $27.78
Upside: +8.01%
ADC Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.29
Upside: +203.95%
ORIC Pharmaceuticals
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $11.00
Upside: +63.64%
Compass Therapeutics
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.53
Upside: +117.00%
BeOne Medicines AG
Aug 7, 2025
Maintains: Buy
Price Target: $350 → $365
Current: $322.90
Upside: +13.04%
Arvinas
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $12.79
Upside: +17.28%
Aug 6, 2025
Maintains: Buy
Price Target: $8 → $10
Current: $9.63
Upside: +3.84%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $38.77
Upside: -56.15%
Jun 25, 2025
Reiterates: Buy
Price Target: $80
Current: $79.64
Upside: +0.45%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $24.69
Upside: +82.26%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $22.98
Upside: -34.73%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $66.62
Upside: -21.95%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $7.68
Upside: +30.21%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $20.32
Upside: +57.48%
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $21.15
Upside: -62.17%
Mar 28, 2025
Reiterates: Buy
Price Target: $109
Current: $96.14
Upside: +13.38%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $10.36
Upside: +35.14%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $28.13
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $44.36
Upside: -5.32%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.53
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.58
Upside: +258.42%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.39
Upside: +475.54%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $38.78
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $7
Current: $0.53
Upside: +1,210.37%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.42
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.40
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $17.30
Upside: +96.53%
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $3.27
Upside: +664.53%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $17.41
Upside: +72.31%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $5.46
Upside: +376.19%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.74
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $27.73
Upside: +188.50%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $7.92
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.42
Upside: +24.43%